The Food and Drug Administration approved a drug tested during the 2018 Ebola epidemic as a treatment for the disease. It’s the first therapy approved by the agency for Ebola, and shows that research done during an emergency can find effective drugs.
“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.
The drug, called Inmazeb, is a mixture of three antibodies that block the Ebola virus. It was developed by Regeneron, which is also testing an antibody treatment for COVID-19. In clinical trials, patients who took Inmazeb were far less likely to die from the…tech, The Verge